KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

Press/Media

Period	Apr 14 2025

Media coverage

Title	KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia
Media name/outlet	MOLECULAR CANCER
Country/Territory	United Kingdom
Date	04/14/25
URL	ct.moreover.com/?a=56503258795&p=1gw&v=1&x=yqo7o03FSeG3QLutOkFAUQ
Persons	Ross Wang